|
|
Glucomannan minimizes the postprandial insulin surge: a potential adjuvant
for hepatothermic therapy.
Med Hypotheses. 2002 Jun;58(6):487-90.
McCarty MF.
Pantox Laboratories, San Diego, Californi 92109, USA.
Glucomannan (GM) is differentiated from other soluble fibers by the
extraordinarily high viscosity of GM solutions. Administration of 4-5g
of GM with meals, blended into fluid or mixed with food, can slow carbohydrate
absorption and dampen the postprandial insulin response by up to 50%.
Controlled clinical studies document that GM can promote satiety and
weight loss, lower LDL cholesterol, improve diabetic control, and correct
constipation, with minimal if any side-effects. Rodent studies suggest
that GM may have potential for decreasing cancer risk and possibly even
slowing the ageing process. Hepatothermic therapy, a technique for achieving
rapid loss of body fat by optimizing the liver's capacity for fat oxidation,
can only achieve its optimal efficacy if diurnal insulin levels are
kept low; ingestion of GM with meals will evidently be of benefit in
this regard by moderating postprandial insulin surges.
|